What the Advisers Decided
A federal advisory panel voted 9 to 3 on July 29 that the available evidence does not support the effectiveness of deramiocel for treating the heart muscle disease that develops in Duchenne muscular dystrophy.
A federal advisory panel voted 9 to 3 on July 29 that the available evidence does not support the effectiveness of deramiocel for treating the heart muscle disease that develops in Duchenne muscular dystrophy.